Variable | Details of the variables | Probability distribution | Source | Range |
---|---|---|---|---|
IPTi-SP a total provider costs in US$ 2007 for the ITT population | Fixed costs to administer 3 doses IPTi-SPa to a hypothetical target of 594 infants + variable costs to administer 1 dose IPTi-SPa to an actual target of 97 infants, 2 doses to 92 infants and 3 doses to 315 infants | Triangular (97.70, 130.26, 162.82) | ±25% | |
IPTi-SP a total provider costs US$ 2007 for the ATP population | Fixed costs to administer 3 doses IPTi-SPa to a hypothetical target of 594 infants + variable costs to administer 3 doses IPTi-SPa to an actual target of 315 infants | Triangular (88.78, 118.38, 147.98) | ±25% | |
Cost-effectiveness analysis - input variables | ||||
Intention to treat (ITT) | ||||
Protective Efficacy 18 months | Protective efficacy of IPTp-SPa to avert anaemia at 18 months follow up (ITT analysis) | Triangular (-0.01,0.22,0.4) | [21] | [21] |
Malaria incidence | Rate per person-years at risk in placebo group | Triangular (0.08,0.16,0.24) | [21] | ±50% |
According to protocol (ATP) | ||||
Protective Efficacy 18 months | Protective efficacy of IPTp-SPa to avert anaemia at 18 months follow up (ATP analysis) | Triangular (0.02, 0.27, 0.46) | [21] | [21] |
Malaria incidence | Rate per person-years at risk in placebo group | Triangular (0.075, 0.15, 0.3) | [21] | ±50% |